Gregory Stock
A recognized expert on the larger implications of today's revolution in the Life Sciences, Dr. Gregory Stock explores the larger evolutionary significance of humanity, which he wrote about in his book, The Merging of Humans and Machines into a Global Superorganism. A leading authority on genomic testing, anti-aging medicine and developmental biology, Dr. Stock is the President and CEO of Signum Biosciences where he is developing therapeutics for Alzheimer's.
Topics:
- Biotechnology /
- Emerging Technology /
- Futurist /
- Science

Dr. Gregory Stock believes we are at a defining moment in human evolution. A thousand years from now our descendants will point to this time, with its critical breakthroughs in computers, genetics and space travel, as one of the key transitions in the long history of life. Dr. Stock has explored the larger evolutionary significance of humanity's recent technological progress for many years, examining the subject at length in his book The Merging of Humans and Machines into a Global Superorganism.
A recognized expert on the larger implications of today's revolution in the Life Sciences, Dr. Stock convened the first major public conference to discuss our potential to select the genes we pass to our children. This symposium drew international attention and opened up a wide public debate on the hitherto taboo topic. He has also convened landmark conferences on genomic testing and anti-aging medicine.
Dr. Stock has published research papers on topics ranging from developmental biology and limb regeneration to laser light scattering, and is on the editorial board of the American Journal of Bioethics, the International Journal of Bioethics, and the Journal of Evolution and Technology. He makes frequent appearances on radio and television, including NPR, CNN, PBS, Bloomberg, and the BBC, speaks regularly to business, government, and academic audiences, has debated biotech policy with Jeremy Rifkin, Leon Kass, Francis Fukuyama, Bill McKibben, George Annas and other prominent voices who would rein in biomedical research, and recently he hosted a television special on key figures in today's biotech revolution.
Dr. Stock received a Ph.D. in biophysics from Johns Hopkins University and an MBA from Harvard Business School. Currently the President and CEO of Signum Biosciences, a company he co-founded in 2002, he is developing therapeutics for Alzheimer's. He is also visiting at Princeton's Woodrow Wilson School, where he is exploring new regulatory possibilities for the pharmaceutical industry.
Check Availability | Program Descriptions | + Add to Wishlist | Login to email this


